Price Action Don’t Lie: Could Flexion Therapeutics Inc Lose Strenght? The Stock Increases A Lot Today

Price Action Don't Lie: Could Flexion Therapeutics Inc Lose Strenght? The Stock Increases A Lot Today

The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) is a huge mover today! About 372,087 shares traded hands. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 34.80% since April 18, 2016 and is uptrending. It has outperformed by 30.37% the S&P500.
The move comes after 6 months positive chart setup for the $501.81 million company. It was reported on Nov, 18 by Barchart.com. We have $22.67 PT which if reached, will make NASDAQ:FLXN worth $120.43M more.

Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage

Out of 7 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Flexion Therapeutics has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. As per Wednesday, November 4, the company rating was initiated by Cantor Fitzgerald. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) has “Buy” rating given on Thursday, July 21 by Lake Street. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned “Buy” rating by Needham on Wednesday, September 9. BMO Capital Markets initiated the shares of FLXN in a report on Wednesday, June 29 with “Outperform” rating. The firm has “Outperform” rating given on Tuesday, May 3 by Wells Fargo.

According to Zacks Investment Research, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1.54 in 2016 Q2. Its down 1.31, from 2.85 in 2016Q1. The ratio is negative, as 9 funds sold all Flexion Therapeutics Inc shares owned while 11 reduced positions. 21 funds bought stakes while 36 increased positions. They now own 18.68 million shares or 38.37% more from 13.50 million shares in 2016Q1.
Blackrock owns 2,018 shares or 0% of their US portfolio. National Bank & Trust Of America Corp De has invested 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Amici Limited Liability Com accumulated 20,000 shares or 0.06% of the stock. Adage Capital Group Inc Limited Liability Co last reported 76,000 shares in the company. Moreover, Barclays Public Limited has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 326 shares. Sabby Lc holds 100,800 shares or 0.08% of its portfolio. Teachers Retirement System Of The State Of Kentucky has invested 0.01% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). State Street Corp holds 225,245 shares or 0% of its portfolio. Citigroup Inc has 3,254 shares for 0% of their US portfolio. Highbridge Management Ltd Liability Co holds 0.01% or 35,577 shares in its portfolio. Bridgeway Cap Mngmt owns 44,000 shares or 0.01% of their US portfolio. Wall Street Associates reported 113,400 shares or 0.68% of all its holdings. Manufacturers Life Insur Com The last reported 13,545 shares in the company. Moreover, Jpmorgan Chase has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 111,975 shares. Millennium Mngmt Limited Liability Com owns 26,028 shares or 0% of their US portfolio.

Insider Transactions: Since May 19, 2016, the stock had 4 insider buys, and 0 selling transactions for $30.01 million net activity. Another trade for 2,000 shares valued at $20,810 was made by Clayman Michael D. on Friday, May 20. The insider Bodick Neil bought $8,500. $13,387 worth of shares were bought by MERRIFIELD C ANN on Tuesday, June 14. Versant Ventures III – LLC bought $10.00 million worth of stock. On Wednesday, June 8 the insider LUBASH BARBARA N bought $10.00M. COLELLA SAMUEL D had bought 714,285 shares worth $10.00M on Wednesday, June 8.

More recent Flexion Therapeutics Inc (NASDAQ:FLXN) news were published by: Fool.com which released: “Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL …” on November 16, 2016. Also Fool.com published the news titled: “Can Flexion Therapeutics Add Some Muscle to Your Portfolio?” on November 17, 2016. Rttnews.com‘s news article titled: “Flexion Therapeutics Inc. (FLXN) Is Losing Ground After Offering Announcement” with publication date: November 15, 2016 was also an interesting one.

FLXN Company Profile

Flexion Therapeutics, Inc., incorporated on November 5, 2007, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company’s lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Firm has not generated any revenue.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment